-

Bruker Releases 2023 Sustainability Report

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today released its 2023 Sustainability Report, highlighting how Bruker’s spirit of ‘Innovation with Integrity’ is advancing science and technology, medicine and health, as well as safety and prosperity in a responsible, sustainable manner. The report also provides an overview of Bruker’s ESG strategy, initiatives and performance.

“We are pleased to introduce this inaugural 2023 Sustainability Report, which showcases our commitment to corporate social responsibility, transparency and progress in many high-impact ESG areas,” said Gerald Herman, Bruker’s Executive Vice President & CFO. “As a global innovation leader in cutting-edge scientific instruments, analytical technologies and life-science solutions, our scientists and engineers support scientific and medical researchers and advanced businesses around the world to better understand molecular, cell and disease biology, to measure and image complex systems, and search for new ways to improve our quality of life. We are especially proud to collaborate closely with many of our customers on ways to ensure a healthier, safer, and more sustainable future.”

Frank H. Laukien, Ph.D., Bruker’s President & CEO, added: “Our 2023 Sustainability Report highlights how Bruker solutions are helping scientists and technicians to address environmental challenges, advance disease research and scientific discovery, identify hazardous materials in our environment, secure the safety and authenticity of our food and materials, advance research and development of next-generation renewable energy technologies, and to improve recycling. It also reviews our initiatives to reduce environmental impact, promote social responsibility, diversity and inclusion, and to exercise the highest standards of corporate governance, all part of our long-term commitment to ‘Innovation with Integrity’.”

To access the Sustainability Report, and for more information regarding Bruker sustainability initiatives, please visit the Corporate Social Responsibility (CSR) section of our website at www.bruker.com/en/about/csr

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom